Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias

PURPOSE: Dinaciclib inhibits cyclin-dependent kinases 1, 2, 5, and 9 with a better therapeutic index than flavopiridol in preclinical studies. This study assessed the activity of dinaciclib in acute leukemia both in the clinic and in vitro. METHODS: Adults with relapsed/refractory acute myeloid leuk...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Gojo, Ivana, Sadowska, Mariola, Walker, Alison, Feldman, Eric J., Iyer, Swaminathan Padmanabhan, Baer, Maria R., Sausville, Edward A., Lapidus, Rena G., Zhang, Da, Zhu, Yali, Jou, Ying-Ming, Poon, Jennifer, Small, Karen, Bannerji, Rajat
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer Berlin Heidelberg 2013
Gaiak:
Clinical Trial Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3784060/
https://ncbi.nlm.nih.gov/pubmed/23949430
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-013-2249-z
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak